帕立骨化醇
Paricalcitol;Zemplar;(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol;19-Nor-1alpha,25-dihydroxyvitamin D2;Paracalcin;(1α,3β,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol solution;(1α, 3β, 7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol;Paricalcitol(Zemplar);19-Nor-1,25- dihydroxyvitaMin D2;1α,25-Dihydroxy-19-nor-vitaMin D2;1,25-DihydroxyvitaMin D2 Paricalcitol;Paricalcitol (10 mg) (COLD SHIPMENT REQUIRED);PARICALCITOL [WHO-DD];Paricalcitol [USAN:USP:INN];paricalcitolum;Q155746;PARICALCITOL [USP-RS];Zemplar (TN);6702D36OG5;(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol;19-Nor-1-alpha,25-dihydroxyvitamin D2;UNII-6702D36OG5;PARICALCITOL (USP IMPURITY);PARICALCITOL [MI];(1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol;(1.ALPHA.3.BETA.,7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1,3,25-TRIOL;BCP9001050;(1R,3R,7E)-17beta-((2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-9,10-secoestra-5,7-diene-1,3-diol;(1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol;(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol;131918-61-1;BIDD:GT0330;Paricalcitol (JAN/USP/INN);GTPL2791;LMST04030163;Compound 49510;HSDB 7360;s6681;BDBM233195;(1alpha,3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol;EX-A4434;HY-50919;D00930;CHEBI:7931;DTXCID7028566;PARICALCITOL (USP MONOGRAPH);Tox21_112987;19-Nor-1,25-(OH)2D2;(7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL;PARICALCITOL [USP MONOGRAPH];Paricalcitol [USAN];PARICALCITOL (USP-RS);PARICALCITOL [USP IMPURITY];PARICALCITOL [HSDB];PARICALCITOL [ORANGE BOOK];H05BX02;MS-27260;PARICALCITOL [JAN];CHEMBL1200622;AKOS005145562;ABT-358;CS-0705;C08127;(1alpha3beta,7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1,3,25-TRIOL;Paricalcitol (USAN:USP:INN);PARICALCITOL (MART.);PARICALCITOL [MART.];A937163;1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-;CAS-131918-61-1;DB00910;(1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol;19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-;AMY2878;Compound-49510;(1R,3R,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol;SCHEMBL3655;PARICALCITOL [VANDF];DTXSID4048640;BPKAHTKRCLCHEA-UBFJEZKGSA-N;NCGC00182706-01;Paricalcitol, >=98%;PARICALCITOL (10 MG)F0E3030.997MG/MG(AI);BRD-K60585088-001-01-5